blinatumomab,ponatinib
otsuka,amgen,takeda,astellas,incyte
['leusm', 'blinatumomab', 'ponatinib', 'ph+ all']
congress| #ash22 , presents the phase ii sub-study results of ponatinib + blinatumomab in pts with nd ph+ all(n=40). it was well tolerated with high rates of cmr(87%) and ngs mrd negativity(88%), and estimated 2-year os of 95% #allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm